# PTC Therapeutics Inc. (PTCT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $69.30, market value $5.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). PTC Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.10**. A PEG of 0.10 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 5.7×**. Each dollar of revenue is priced at 5.7×.
- **EV / EBITDA: 28.1×**. Enterprise value is 28.1× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: -0.7%** (5-yr avg -5.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: 12.5%**. 12.5% of revenue is left after running the business.
- **Net margin: 39.4%**. 39.4% of each dollar of sales reaches the bottom line.
- **Return on equity: -332.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -11.0%**. Return on all capital, debt included, is -11.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -1.3%**. Each dollar of assets produces -1.3% of profit.

## Growth
- **Revenue growth (1 yr): 114.5%** (3-yr 35.3%/yr, 5-yr 35.4%/yr). Revenue grew 114.5% over the last year, against 35.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 264.5%**. Earnings per share rose 264.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: net cash**. PTC Therapeutics Inc. holds more cash than debt.
- **Altman Z-score: 2.60**. A Z-score of 2.60 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. PTC Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (14 analysts). 14 analysts cover PTC Therapeutics Inc.; the consensus is buy, with an average price target of $99.29 (+43% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 19.5%** (YTD -8.8%, 3-mo -2.4%). The shares are up 19.5% over twelve months including dividends.
- **From 52-week high: -23.7%** (21.7% above the low). Trading 24% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 0.77** (volatility 40%). Beta of 0.77 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PTCT · Page: https://foliofundamentals.com/stocks/ptct

Not investment advice.